ArticleBiosensors2026
A High-Precision Screen-Printed Glucose Sensor with In Situ Impedance-Based HCT Correction and Temperature Compensation.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hematocrit (HCT) fluctuations and ambient temperature variations are two critical interference factors limiting the accuracy of electrochemical glucose test strips in self-monitoring of blood glucose (SMBG). In this study, a high-precision screen-printed glucose sensor incorporating in situ impedance-based HCT correction and temperature compensation was developed. The system employs a time-division multiplexing strategy, integrating a normalized thermodynamic model and an in situ impedance-based HCT correction algorithm, to achieve synergistic decoupling and precise compensation of temperature and HCT interferences. Experimental results demonstrate that after multi-parameter synergistic correction, the system exhibits excellent stability across a wide temperature range (10-35 °C) and a broad HCT range (10-70%). The accuracy indicators significantly surpass ISO 15197:2013 standards. In contrast, uncorrected measurements showed deviations ranging from approximately -80% to +30% due to HCT fluctuations. This multiple correction strategy effectively resolves systematic errors in whole blood testing without increasing electrode complexity or requiring pretreatment steps, providing a robust technical solution for high-precision, low-cost personal glucose monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.